Answers are grounded in this paper and cite their sources.
Rheumatoid Arthritis (RA) is a chronic auto-immune disease that mostly occurs in joint space with remarkably painful swelling. RA detail pathologies remain unclear, but several C-C motif chemokines factors and Interleukin have been identified as associated factors and correlated disease-associate activities (such as CCL2, CCL18, IL-6). Among these factors, increasing evidence indicates CCL18 could be an appropriate drug target, as it is highly correlated with disease-associated activities (DAS28) (elevated level of CCL18 in both patient serum and local synovial fluids). High-concentration CCL18 in synovial fluids has been reported to facilitate pro-inflammation factor production, finally resulting in painful swelling in joint space. In vivo studies showed significant drug efficiency with anti-TNF-a treatment (CCl18 suppression). Most current approved drugs target TNF, IL-6, or other factors, but do not target CCL18 directly or indirectly. From this perspective, CCL18 has been believed to be a new target for RA therapeutic drug development.
No takes yet. Share an insight, caveat, or question.
Tan Yuebin (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: